Nuron Biotech to Develop Long-acting Version of Proprietary Recombinant Human Interferon Beta-1b Utilizing PolyTherics’ TheraPEG(TM) PEGylation Technology
5/27/2011 11:08:49 AM
Nuron Biotech Inc., a specialty biologics and vaccines company, today announced that it has secured an exclusive option and license agreement utilizing PolyTherics’ site-specific TheraPEG™ PEGylation technology to develop NU400, a long-acting version of Nuron’s proprietary recombinant human interferon beta-1b (NU100). PEGylating NU100 can also potentially improve other properties including its solubility, stability and safety profile. NU100 is poised to enter Phase 3 clinical studies in 2011 based on recent positive regulatory advice from the European Medicines Agency (EMEA).
comments powered by